The landscape of human epidermal growth factor receptor 2 (HER2)-targeted therapies continues to evolve rapidly. For oncology researchers and drug developers, Trastuzumab botidotin (development code: A166) represents a significant leap forward in the engineering of next-generation antibody-drug conjugates (ADCs).

Recently achieving its first regulatory approval by China's National Medical Products Administration (NMPA) in October 2025, Trastuzumab botidotin is generating heavy interest following its impressive clinical outperformance of standard therapies like T-DM1 (trastuzumab emtansine).

Here is everything researchers need to know about the structural profile, mechanism of action (MoA), manufacturer details, and latest clinical data for Trastuzumab botidotin.

Trastuzumab botidotin is a highly differentiated, third-generation ADC designed to maximize tumor-specific killing while minimizing systemic, off-target toxicity. The construct consists of three meticulously engineered components:

• The Antibody: A recombinant humanized IgG1 anti-HER2 monoclonal antibody (trastuzumab), which provides the targeted delivery vehicle.

• The Linker: A highly stable, protease-cleavable valine-citrulline (Val-Cit) linker. This ensures the cytotoxic payload remains securely attached in systemic circulation but is efficiently cleaved by intracellular enzymes (like cathepsin B) within the tumor microenvironment.

• The Payload (Duo-5): The antibody is conjugated to Duostatin-5 (Duo-5), a novel monomethyl auristatin F (MMAF) derivative. Duo-5 is a highly potent anti-mitotic agent and tubulin inhibitor.

• Conjugation Technology: Unlike early-generation ADCs that relied on stochastic conjugation (yielding heterogeneous mixtures), Trastuzumab botidotin utilizes proprietary site-specific K-Lock™ conjugation chemistry. This results in a highly stable and uniform Drug-to-Antibody Ratio (DAR) of exactly 2.

Trastuzumab botidotin exerts its antineoplastic activity through a multi-step mechanism characteristic of advanced ADCs, combined with the inherent immune properties of its base antibody:

1. Receptor Binding: The IgG1 antibody binds with high affinity to the extracellular domain IV of the HER2 receptor on the surface of overexpressing tumor cells.

2. Internalization & Cleavage: Upon binding, the ADC-HER2 complex undergoes rapid receptor-mediated endocytosis. Once inside the lysosome, the acidic environment and protease enzymes cleave the Val-Cit linker.

3. Cytotoxicity: The cleaved Duo-5 payload is released into the cytoplasm. It binds to tubulin, severely disrupting the microtubule network required for cell division. This induces cell cycle arrest at the G2/M phase, ultimately triggering cellular apoptosis.

4. Inhibition of Signaling & ADCC: Even while conjugated, the trastuzumab moiety continues to block downstream HER2 signaling pathways (such as PI3K/AKT and MAPK). Furthermore, the Fc region of the antibody retains its ability to engage immune effector cells, driving robust Antibody-Dependent Cellular Cytotoxicity (ADCC).

Trastuzumab botidotin recently made headlines at the ESMO Congress 2025, where Professor Xichun Hu presented the results of the pivotal Phase 3 trial (KL166-III-06; NCT06968585).

The trial evaluated Trastuzumab botidotin against T-DM1 in 365 patients with HER2-positive unresectable or metastatic breast cancer (mBC) who had previously been treated with a taxane and trastuzumab.

The results demonstrated a statistically significant and clinically meaningful superiority over T-DM1 across primary endpoints:

Trastuzumab botidotin was generally well-tolerated. While ocular adverse events (such as corneal disorders and dry eye) were relatively common due to the payload profile, they were highly manageable and largely reversible with dose adjustments. Notably, occurrences of interstitial lung disease (ILD) / pneumonitis—a common concern with other ADCs like Trastuzumab deruxtecan (T-DXd)—were exceptionally low (1.1%).

Trastuzumab botidotin was originated by KLUS Pharma (the US-based research subsidiary) and is being primarily developed and commercialized by its parent company, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Following its October 2025 approval by the NMPA for second-line and later treatment of HER2-positive metastatic breast cancer in China, Kelun-Biotech is actively expanding the drug's clinical footprint. Beyond breast cancer, Trastuzumab botidotin is currently being investigated in early-phase clinical trials for a variety of other HER2-expressing solid tumors, including non-small cell lung cancer (NSCLC), gastric cancer, and colorectal cancer.

While Trastuzumab botidotin is making waves in the clinic, your lab might be looking for specialized tools to match the pace of ADC innovation. At ichorbio, we specialize in high-quality research biosimilars and custom antibody engineering. Whether you need precise conjugation, custom payload attachments, or specialized biosimilar development for your preclinical assays, our custom services team is ready to build the exact molecule your research demands.